Belinostat: clinical applications in solid tumors and lymphoma

Bibliography

• Khorasanidazeh S. The nucleosome: from genomic organization to genomic regulation. Cell 2004;116:259-72
   PubMed Web of Science ®Google Scholar
• Grunstein M. Histone acetylation in chromatin structure and transcription. Nature 1997;389:349-52
   PubMed Web of Science ®Google Scholar
• Johnstone RE, Licht JD. Histone deacetylase inhibitors in cancer therapy: is transcription the primary target? Cancer Cell 2003;4:13-18
   PubMed Web of Science ®Google Scholar
• Yang XJ, Gregoire S. Class II histone deacetylases:from sequence to function, regulation, and clinical implication. Mol Cell Biol 2005;25:2873-84
   PubMed Web of Science ®Google Scholar
• Chen L. Medicinal chemistry of sirtuin inhibitors. Curr Med Chem 2001;18:1936-46
   Google Scholar
• Marks PA, Dokmanovic M. Histone deacetylase inhibitors: discovery and development as anticancer agents. Expert Opin Investig Drugs 2005;14:1497-511
   PubMed Web of Science ®Google Scholar
• Bolden JE, Peart MJ, Jhnstone RW. Anticancer activities of histone deacetylase inhibitors. Nat Rev Drug Discov 2006;5:769-84
   PubMed Web of Science ®Google Scholar
• Park JH, Jung Y, Kim TY, Class I histone deacetylase-selective novel synthetic inhibitors potently inhibit human tumor proliferation. Clin Cancer Res 2004;10:5271-81
   PubMed Web of Science ®Google Scholar
• Huang BH, Laban M, Leung CH, Inhibition of histone deacetylase 2 increases apoptosis and p21CIp1/WAF1 expression, independent of histone deacetylase 1. Cell Death Differ 2005;12:395-404
   PubMed Web of Science ®Google Scholar
• Dequiedt F, Kasler H, Fischle W, HDAC7, a thymus-specific class II histone deacetylase, regulates Nur77 transcritpion and TCR-mediated apoptosis. Immunity 2003;18:687-98
   PubMed Web of Science ®Google Scholar
• Fiskus W, Ren Y, Mohaptra A, Hydroxyamic acid analogue histone deacetylase inhibitors attenuate estrogen receptor-alpha levels and transcriptional activity: a result of hyperacetylation and inhibition of chaperone function of heat shock protein 90. Clin Cancer Res 2007;13:4882-90
   PubMed Web of Science ®Google Scholar
• Glozak MA, Sengupta N, Zhang X, Seto E. Acetylation and deacetylation of non-histone proteins. Gene 2005;363:15-23
   PubMed Web of Science ®Google Scholar
• Kovacs JJ, Murphy PJ, Gaillard S, HDAC6 regulates Hsp() acetylation and chaperone dependent activation of glucocorticoid receptor. Mol Cell 2005;18:601-7
   PubMed Web of Science ®Google Scholar
• Hubbert C, Guardiola A, Shao R, HDAC6 is a microtubule-associated deacetylase. Nature 2002;417:455-8
   PubMed Web of Science ®Google Scholar
• Marks PA, Rifkind RA, Richon VM, Breslow R. Inhibitors of histone deacetylase are potentially effective anticancer agents. Clin Cancer Res 2001;7:759-60
   PubMed Web of Science ®Google Scholar
• Dokmanovic M, Marks PA. Prospects: histone deacetylase inhibitors. J Cell Biochem 2005;96:293-304
   PubMed Web of Science ®Google Scholar
• Glaser KB, Staver MJ, Waring JF, Gene expression profiling of multiple histone deacetylase (HDAC) inhibitors: defining a common gene set produced by HDAC inhibition in T24 and MDA carcinoma cell lines. Mol Cancer Ther 2003;2:151-63
   PubMed Web of Science ®Google Scholar
• Ellis L, Pan Y, Smyth GK, Histone deacetylase inhibitor panobinostat induces clinical responses with associated alterations in gene expression profiles in cutaneous T-cell lymphoma. Clin Cancer Res 2008;14:4500-10
   PubMed Web of Science ®Google Scholar
• Mann BS, Johnson JR, Cohen MH, FDA approved summary: vorinostat for treatment of advanced primary cutaneous T-cell lymphoma. Oncologist 2007;12:1247-52
   PubMed Web of Science ®Google Scholar
• Mann BS, Johnson JR, He K, Vorinostat for treatment of cutaneous manisfestations of advanced primary cutaneous T-cell lymphoma. Clin Cancer Res 2007;13:2318-22
   PubMed Web of Science ®Google Scholar
• Piekarz RL, Frye R, Turner M, Phase II multi-institutional trial of the histone deacetylase inhibitor romidepsin as monotherapy for patients with cutaneous T-cell lymphoma. J Clin Oncol 2009;27:5410-17
   PubMed Web of Science ®Google Scholar
• Piekarz RL, Frye R, Prince HM, Phase II trial of romidepsin in patients with peripheral T-cell lymphoma. Blood 2011;117:5827-34
   PubMed Web of Science ®Google Scholar
• Tan J, Cang S, Ma Y, Novel histone deacetylase inhibitors in clinical trials as anti-cancer agents. J Hematol Oncol 2010;3:5
   PubMed Web of Science ®Google Scholar
• Plumb JA, Finn PW, Williams RJ, Pharmacodynamic response and inhibition of growth of human tumor xenografts by the novel histone deacetylase inhibitors PXD101. Mol Cancer Ther 2003;2:721-8
   PubMed Web of Science ®Google Scholar
• Khan N, Jeffers M, Kumar S, Determination of the class and isoform selectivity of small molecule histone deacetylase inhibitors. Biochem J 2008;409:581-9
   PubMed Web of Science ®Google Scholar
• Steele N. Olumb JA, Vidal, L, et al. A phase I pharmacokinetic and pharmacodynamic study of the histone deacetylase inhibitor belinostat in patients with advanced solid tumors. Clin Cancer Res 2008;14:804-10
   PubMed Web of Science ®Google Scholar
• Gimsing P, Hansen M, Knudsen LM, A phase I clinical trial of the histone deacetylase inhibitor belinostat in patients with advanced haematological neoplasia. Eur J Haematol 2008;81:170-6
   PubMed Web of Science ®Google Scholar
• Steele NL, Plumb JA, Vidal L, Pharmacokinetic and pharmacodynamis properties of an oral formulation of the histone deacetylase inhibitor belinostat (PXD101). Cancer Chemother Pharmacol 2001;67:1273-9
   Web of Science ®Google Scholar
• Molife R, Lee J, Petrylak D, A phase I study of oral belinostat (PXD101) in paitents with advanced solid tumors. Mol Cancer Ther 2007;6:3476S
   Web of Science ®Google Scholar
• Kelly WmK, Blumenschein G, Lassen U, Final results of a phase I study of oral belinostat (PXD101) in patients with solid tumors. J Clin Oncol 2009;27:3531
   Google Scholar
• Zain J, Moss F, de Bono J, Interim results of a phase I trial of an oral histone deacetylase inhibitor belinostat in patients with lymphoid malignancies. Blood 2010;116:1787
   PubMed Web of Science ®Google Scholar
• Qian X, LaRochelle WJ, Ara G, Activity of PXD101,a histone deacetylase inhibitor, in preclinical ovarian cancer studies. Mol Cancer Ther 2006;5:2086-95
   PubMed Web of Science ®Google Scholar
• Tumber A, Collins LS, Petersen KD, The histone deacetylase inhibitor PXD101 synergises with 5-fluorouracil to inhibit colon cancer cell growth in vitro and in vivo. Cancer Chemother Pharmacol. 2007;60:275-83
   PubMed Web of Science ®Google Scholar
• Na YS, Jung KA, Kim SM, The histone deacetylase inhibitor PXD101 increases the efficacy of irinotecan in in vitro and in vivo colon cancer models. Cancer Chemother Pharmacol 2001;68:389-98
   Web of Science ®Google Scholar
• Lassen U, Molife LR, Sorensen M, A phase I study of the safety and pharmacokinetics of the histone deacetylase inhibitor belinostat administered in combination with carboplatin and/or paclitaxel in patients with solid tumors. Br J Cancer 2010;103:12-17
   PubMed Web of Science ®Google Scholar
• Brunetto AT, Krarup-Hansen A, Nielsen OS, A phase I clinical trial of belinostat (PXD101) in combination with doxorubicin (BelDox) in advanced solid tumours including soft tissue sarcomas (STS). Eur J Cnacer 2008;6:132
   Web of Science ®Google Scholar
• Northfelt DW, Bonnem E, Fagerberg J, Belinostat (Bel) down-regulates thymidylate synthase (TS) in tumor tissue: a dose escalation study of belinostat alone and in combinatiom with 5-fluorouracil (5FU). Proceedings, 2009 Gastrointestinal Cancers Symposium; 2009. p. 333
   Google Scholar
• Odenike O, Green M, Larson A, Phase I study of belinostat (PXD101) plus azacitidine (AZC) in patients with advanced myeloid malignancies. J Clin Oncol 2008;26:7057
   Google Scholar
• Sorenson M, Tjornelund J, Jensen PB. A phase I study and pharmacokinetic (PK) study of 3 and 6 hours (h) intravenously administered belinostat (PXD101) plus carboplatin (C) and paclitaxel (P) in patients (pts) with advanced. Eur J Cancer 2008;6:132
   Web of Science ®Google Scholar
• Buckley MT, Yoon J, Yee H, The histone deacetylase inhibitor belinostat (PXD101) suppresses bladder cancer cell growth in vitro and in vivo. J Transl Med 2007;5:49
   PubMed Web of Science ®Google Scholar
• Jordan MA, Wilson L. Microtubules as a target for anticancer drugs. Nat Rev Cancer 2004;4:253-65
   PubMed Web of Science ®Google Scholar
• Westermann S, Webe K. Post translational modifications regulate microtubule function. Nat Rev Mol Cell Biol 2003;4:938-47
   PubMed Web of Science ®Google Scholar
• Thiriet C, Hayes JJ. Chromatin in need of a fix: phosphorylation of H2AX connects chromatin to DNA repair. Mol Cell 2005;18:617-22
   PubMed Web of Science ®Google Scholar
• Huang X, Okafuji M, Traganos F, Assessment of histone H2AX phosphorylation induced by DNA topoisomerase I and II inhibitors topotecan and mitoxantrone and by the DNA cross-linking agent cisplatin. Cytometry A 2004;58:99-110
   PubMed Web of Science ®Google Scholar
• Copur S, Aiba K, Drake JC, Thymidylate synthase gene amplification in human colon cancer cell lines resistant to 5-fluorouracil. Biochem Pharmacol 1995;49:1419-26
   PubMed Web of Science ®Google Scholar
• Paoluzzi L, Scotto L, Marchi E, Romidepsin and belinostat synergize the antineoplastic effect of bortezomib in mantle cell lymphoma. Clin Cancer Res 2010;16:554-65
   PubMed Web of Science ®Google Scholar
• Nallapreddy S, Leong SM, CamidgeR, A phase I study of belinostat (PXD101) in combination with bortezomib in patients with advanced solid tumors or lymphoma. Mol Cancer Ther 2009;8:B238
   Google Scholar
• Paik PK, Krug LM. Histone deacetylase inhibitors in malignant pleural mesothelioma: preclinical rationale and clinical trials. J Thorac Oncol 2010;5:275-9
   PubMed Web of Science ®Google Scholar
• Krug LM, Curley T, Schwartz L, Potential role of histone deacetylase inhibitors in mesothelioma: clinical experience with suberoylanilide hydroxamic acid. Clin Lung Cancer 2006;7:257-61
   PubMed Web of Science ®Google Scholar
• Ramalingam SS, Belani CP, Ruel C, Phase II study of belinostat (PXD101), a histone deacetylase inhibitor, for second line therapy of advanced malignant pleural mesothelioma. J Thorac Oncol 2009;4:97-101
   PubMed Web of Science ®Google Scholar
• Ma BB, Sung F, Tao Q, The preclinical activity of the histone deacetylase inhibitor PXD101 (belinostat) in hepatocellular carcinoma cell lines. Invest New Drugs 2010;28:107-14
   PubMed Web of Science ®Google Scholar
• Yeo W, Lim R, Ma BB, A phase I/II study of belinostat (PXD101) in patients with unresectable hepatocellular carcinoma. J Clin Oncol 2007;25:15081
   Google Scholar
• Mackay HJ, Hirte H, Colgan T, Phase II trial of the histone deacetylase inhibitor belinostat in women with platinum resistant epithelial ovarian cancer and micropapillary (LMP) ovarian tumours. Eur J Cancer 2010;46:1573-9
   PubMed Web of Science ®Google Scholar
• Giaccone G, Rajan A, Berman A, Phase II study of belinostat in patients with recurrent or refractory advanced thymic epithelial tumors. J Clin Oncol. 2011;29:2052-9
   PubMed Web of Science ®Google Scholar
• Marquard L, Poulsen CB, Gjerdrum LM, Histone deacetylase 1, 2, and acetylated histone H4 in B-and T-cell lymphomas. Histopathology 2009;54:688-98
   PubMed Web of Science ®Google Scholar
• Pohlman B, Advani R, Duvic M, Final results of a phase II trial of belinostat (PXD101) in patients with recurrent or refractory peripheral or cutaneous T-cell lymphoma. Blood 2009;114:920
   Web of Science ®Google Scholar
• BarriusoJ, daugaard G, FrentzasS, Phase II multi-centre trial of belinostat (PXD101) in combination with carboplatin and paclitaxel (BELCAP) for patients (pts) with transitional cell carcinoma (TCC) of the bladder. Eur J Cancer 2008;6:213
   Web of Science ®Google Scholar
• Finkler NJ, Dizon DS, Braly P, Phase II multicenter trial of the histone deacetylase inhibitor (HDACi) belinostat, carboplatin and paclitaxel (BelCaP) in patients (pts) with relapsed ovarian cancer. J Clin Oncol 2008;26:5519
   Google Scholar
• Daugaard G, Fizazi K, Huebner G, An open label randomized phase II trial of belinostat (PXD101) in combination with carboplatin and paclitaxel (BelCaP) compared to carboplatin and paclitaxel in patients with previously untreated carcinoma unknown primary. J Clin Oncol 2010;28:TPS185
   Web of Science ®Google Scholar
• Bruserud O, Stapnes E, Ersvaer BT, Histone deacetylase inhibitors in cancer treatment: a review of the clinical toxicity and the modulation of gene expression in cancer cells. Curr Pharm Biotechnol 2007;8:388-400
   PubMed Web of Science ®Google Scholar
• Molife R, Fong P, Scurr M, HDAC inhibitors and cardiac safety. Clin Cancer Res 2007;13:1068
   PubMed Web of Science ®Google Scholar
• Stimson L, La Thangue NB. Biomarkers for predicting clinical responses to HDAC inhibitors. Cancer Lett 2009;280:177-83
   PubMed Web of Science ®Google Scholar
• Sandor V, Senderowicz A, Mertins S, P21-dependent g(1) arrest with downregulation of cyclin D1 and upregulation of cyclin E by the histone deacetylase inhibitor FR901228. Br J Cancer 2000;83:817-25
   PubMed Web of Science ®Google Scholar
• Vrana J, Decker R, Johnson C, Induction of apoptosis in U937 human leukemia cells by suberoylanilide hydroxamic acid (SAHA) proceeds through pathways that are regulated by Bcl-2/Bcl-XL, c-Jun, and p21CIP1, but independent of p53. Oncogene 1999;18:7016-25
   PubMed Web of Science ®Google Scholar
• Weichert W, Roske A, Niesporek S, Class I histone deacetylase expression has independent prognostic impact in human colorectal cancer: specific role of class I histone deacetylases in vitro and in vivo. Clin Cancer Res 2008;14:1669-77
   PubMed Web of Science ®Google Scholar
• Weichert W, Roske A, Gekeler V, Histone deacetylases 1, 2 and 3 are highly expressed in prostate cabcer and HDAC2 expression is associated with shorter PSA relapse time after radical prostatectomy. Br J Cancer 2008;98:604-10
   PubMed Web of Science ®Google Scholar
• Marquard L, Gjerdrum LM, Christensen IJ, Prognostic significance of the therapeutic targets histone deacetylase 1, 2, 6 and acetylated histone H4 in cutaneous T-cell lymphoma. Histopathology 2008;53:267-77
   PubMed Web of Science ®Google Scholar
• Monks A, Hose CD, Pezzolo P, Gene expression-signature of belinostat in cell lines is specific for histone deacetylase inhibitor treatment, with a corresponding signature in xenografts. Anticancer Drugs 2009;20:682-92
   PubMed Web of Science ®Google Scholar
• Dejligbjerg M, Grausland M, Christensen IJ, Identification of predictive biomarkers for the histone deacetylase inhibitor belinostat in a panel of human cancer cell lines. Cancer Biomark 2008;4:101-9
   PubMed Web of Science ®Google Scholar
• Fotheringham S, Epping MT, Stimson L, Genome-wide loss-of-function screen reveals an important role for the proteasome in HDAC inhibitor-induced apoptosis. Cancer Cell 2009;15:57-66
   PubMed Web of Science ®Google Scholar